NASDAQ:ABCL AbCellera Biologics (ABCL) Stock Forecast, Price & News $6.76 -0.21 (-3.01%) (As of 03:45 PM ET) Add Compare Share Share Today's Range$6.69▼$6.9950-Day Range$5.66▼$7.6252-Week Range$5.53▼$14.97Volume1.46 million shsAverage Volume1.92 million shsMarket Capitalization$1.95 billionP/E RatioN/ADividend YieldN/APrice Target$25.57 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media AbCellera Biologics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside274.9% Upside$25.57 Price TargetShort InterestBearish13.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.06Based on 7 Articles This WeekInsider TradingAcquiring Shares$1.10 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.57) to ($0.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.07 out of 5 starsMedical Sector1057th out of 1,980 stocksPharmaceutical Preparations Industry519th out of 978 stocks 3.5 Analyst's Opinion Consensus RatingAbCellera Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.57, AbCellera Biologics has a forecasted upside of 274.9% from its current price of $6.82.Amount of Analyst CoverageAbCellera Biologics has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.52% of the float of AbCellera Biologics has been sold short.Short Interest Ratio / Days to CoverAbCellera Biologics has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.Change versus previous monthShort interest in AbCellera Biologics has recently increased by 8.52%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAbCellera Biologics does not currently pay a dividend.Dividend GrowthAbCellera Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABCL. Previous Next 3.9 News and Social Media Coverage News SentimentAbCellera Biologics has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for AbCellera Biologics this week, compared to 3 articles on an average week.Search Interest63 people have searched for ABCL on MarketBeat in the last 30 days. This is an increase of 62% compared to the previous 30 days.MarketBeat Follows12 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AbCellera Biologics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,096,885.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders30.30% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.19% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.57) to ($0.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AbCellera Biologics is -37.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AbCellera Biologics is -37.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbCellera Biologics has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AbCellera Biologics (NASDAQ:ABCL) StockAbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Read More Receive ABCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address ABCL Stock News HeadlinesMay 30, 2023 | americanbankingnews.comAbCellera Biologics Inc. (NASDAQ:ABCL) Short Interest UpdateMay 29, 2023 | finance.yahoo.comAbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023June 1, 2023 | Edge On The Street (Ad)AI Getting Close to Thinking Like HumansTechnology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.May 27, 2023 | finance.yahoo.comStrong week for AbCellera Biologics (NASDAQ:ABCL) shareholders doesn't alleviate pain of one-year lossMay 24, 2023 | markets.businessinsider.comAbCellera Biologics (ABCL) Gets a Buy from Berenberg BankMay 24, 2023 | finance.yahoo.comThese Small-Cap Biotech Stocks Have the Wind at Their BackMay 24, 2023 | finance.yahoo.comUPDATE 1-AbCellera to make C$701 million co-investment in CanadaMay 24, 2023 | ca.finance.yahoo.comAbCellera to make C$701 million co-investment in CanadaJune 1, 2023 | Edge On The Street (Ad)AI Getting Close to Thinking Like HumansTechnology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.May 24, 2023 | finance.yahoo.comAbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to PatientsMay 24, 2023 | americanbankingnews.comAbCellera Biologics (NASDAQ:ABCL) Stock Price Up 7.7%May 21, 2023 | fool.comAbCellera Biologics (NASDAQ: ABCL)May 20, 2023 | americanbankingnews.comAbCellera Biologics Inc. (NASDAQ:ABCL) Receives $25.57 Consensus Price Target from AnalystsMay 7, 2023 | seekingalpha.comAbCellera Biologics Inc. (ABCL) Q1 2023 Earnings Call TranscriptMay 6, 2023 | finance.yahoo.comAbCellera Biologics First Quarter 2023 Earnings: EPS Misses ExpectationsMay 6, 2023 | americanbankingnews.comAbCellera Biologics (NASDAQ:ABCL) Price Target Cut to $15.00 by Analysts at SVB SecuritiesMay 6, 2023 | msn.comCredit Suisse Maintains AbCellera Biologics (ABCL) Outperform RecommendationMay 5, 2023 | finance.yahoo.comQ1 2023 Abcellera Biologics Inc Earnings CallMay 5, 2023 | markets.businessinsider.comBerenberg Bank Sticks to Their Buy Rating for AbCellera Biologics (ABCL)May 5, 2023 | finance.yahoo.comAbCellera Biologics (ABCL) Q1 2023 Earnings Call TranscriptMay 4, 2023 | msn.comRecap: AbCellera Biologics Q1 EarningsMay 4, 2023 | finance.yahoo.comAbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Tops Revenue EstimatesMay 2, 2023 | americanbankingnews.comAbCellera Biologics (ABCL) Scheduled to Post Earnings on ThursdayApril 27, 2023 | msn.comEli Lilly posts Q1 contraction amid hit to COVID salesApril 26, 2023 | americanbankingnews.comBrokers Issue Forecasts for AbCellera Biologics Inc.'s Q1 2023 Earnings (NASDAQ:ABCL)April 25, 2023 | msn.comUnusual Call Option Trade in AbCellera Biologics (ABCL) Worth $27.13KApril 25, 2023 | americanbankingnews.comAbCellera Biologics Inc. (NASDAQ:ABCL) Receives $27.33 Consensus PT from AnalystsSee More Headlines ABCL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABCL Company Calendar Last Earnings5/04/2023Today6/01/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABCL CUSIPN/A CIK1703057 Webwww.abcellera.com Phone604-559-9005FaxN/AEmployees386Year FoundedN/APrice Target and Rating Average Stock Price Forecast$25.57 High Stock Price Forecast$34.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+266.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$158.52 million Net Margins-27.71% Pretax Margin-22.02% Return on Equity-4.09% Return on Assets-3.24% Debt Debt-to-Equity RatioN/A Current Ratio10.50 Quick Ratio10.50 Sales & Book Value Annual Sales$485.42 million Price / Sales4.15 Cash Flow$0.67 per share Price / Cash Flow10.38 Book Value$4.19 per share Price / Book1.66Miscellaneous Outstanding Shares288,730,000Free Float201,243,000Market Cap$2.01 billion OptionableNot Optionable Beta-0.12 Key ExecutivesDr. Carl L.G. Hansen Ph.D. (Age 48)CEO, Pres & Chairperson Comp: $616.66kMr. Andrew Booth M.B.A. (Age 49)Chief Financial Officer Comp: $563.57kDr. Veronique Lecault Ph.D. (Age 38)COO & Director Comp: $563.57kMr. Tryn T. Stimart Esq. (Age 53)J.D., Chief Legal Officer, Chief Compliance Officer & Corp. Sec. Comp: $563.8kDr. Ester Falconer Ph.D. (Age 48)Chief Technology Officer Mr. Bo Barnhart Ph.D.Scientific DirectorMs. Tiffany Chiu B.Sc.Ph.D., VP of CommunicationsMr. Murray McCutcheon Ph.D.Sr. VP of Corp. Devel.Alexandra Weirich M.Sc.Mang. of Marketing & CommunicationsCaitlin Webster CIPDM.Sc., Sr. Mang. of People & CultureMore ExecutivesKey CompetitorsVentyx BiosciencesNASDAQ:VTYXCureVacNASDAQ:CVACViking TherapeuticsNASDAQ:VKTXBELLUS HealthNASDAQ:BLUHUTCHMEDNASDAQ:HCMView All CompetitorsInsiders & InstitutionsHoldings Ltd. ThermopylaeBought 153,000 shares on 5/26/2023Total: $997,560.00 ($6.52/share)Andrew BoothBought 14,500 shares on 5/26/2023Total: $99,325.00 ($6.85/share)ProShare Advisors LLCSold 5,989 shares on 5/26/2023Ownership: 0.015%Ameriprise Financial Inc.Bought 47,846 shares on 5/22/2023Ownership: 0.101%JPMorgan Chase & Co.Bought 118,102 shares on 5/18/2023Ownership: 0.246%View All Insider TransactionsView All Institutional Transactions ABCL Stock - Frequently Asked Questions Should I buy or sell AbCellera Biologics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABCL shares. View ABCL analyst ratings or view top-rated stocks. What is AbCellera Biologics' stock price forecast for 2023? 8 Wall Street analysts have issued 1 year target prices for AbCellera Biologics' stock. Their ABCL share price forecasts range from $15.00 to $34.00. On average, they anticipate the company's stock price to reach $25.57 in the next year. This suggests a possible upside of 266.9% from the stock's current price. View analysts price targets for ABCL or view top-rated stocks among Wall Street analysts. How have ABCL shares performed in 2023? AbCellera Biologics' stock was trading at $10.13 on January 1st, 2023. Since then, ABCL shares have decreased by 31.2% and is now trading at $6.97. View the best growth stocks for 2023 here. Are investors shorting AbCellera Biologics? AbCellera Biologics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 26,620,000 shares, an increase of 8.5% from the April 30th total of 24,530,000 shares. Based on an average daily trading volume, of 1,970,000 shares, the days-to-cover ratio is currently 13.5 days. Currently, 13.5% of the company's stock are short sold. View AbCellera Biologics' Short Interest. When is AbCellera Biologics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our ABCL earnings forecast. How were AbCellera Biologics' earnings last quarter? AbCellera Biologics Inc. (NASDAQ:ABCL) announced its quarterly earnings data on Thursday, May, 4th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.02. The company had revenue of $12.20 million for the quarter, compared to analysts' expectations of $12.11 million. AbCellera Biologics had a negative net margin of 27.71% and a negative trailing twelve-month return on equity of 4.09%. The firm's revenue was down 96.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.54 EPS. What ETFs hold AbCellera Biologics' stock? ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), TrueShares Technology, AI & Deep Learning ETF (LRNZ), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB), iShares Biotechnology ETF (IBB), Renaissance IPO ETF (IPO) and When did AbCellera Biologics IPO? (ABCL) raised $356 million in an initial public offering on Friday, December 11th 2020. The company issued 23,000,000 shares at $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO. What is AbCellera Biologics' stock symbol? AbCellera Biologics trades on the NASDAQ under the ticker symbol "ABCL." Who are AbCellera Biologics' major shareholders? AbCellera Biologics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (6.89%), BlackRock Inc. (4.74%), Credit Suisse AG (1.60%), State Street Corp (1.17%), Federated Hermes Inc. (1.01%) and Renaissance Technologies LLC (0.97%). Insiders that own company stock include Andrew Booth, Andrew Lo, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, John S Montalbano, Michael R Hayden and Veronique Lecault. View institutional ownership trends. How do I buy shares of AbCellera Biologics? Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AbCellera Biologics' stock price today? One share of ABCL stock can currently be purchased for approximately $6.97. How much money does AbCellera Biologics make? AbCellera Biologics (NASDAQ:ABCL) has a market capitalization of $2.01 billion and generates $485.42 million in revenue each year. The company earns $158.52 million in net income (profit) each year or ($0.18) on an earnings per share basis. How many employees does AbCellera Biologics have? The company employs 386 workers across the globe. How can I contact AbCellera Biologics? The official website for the company is www.abcellera.com. The company can be reached via phone at 604-559-9005 or via email at ir@abcellera.com. This page (NASDAQ:ABCL) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.